Published in PLoS Curr on August 30, 2011
An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease. PLoS Curr (2011) 0.81
Translational research in Huntington's disease: opening up for disease modifying treatment. Transl Neurodegener (2013) 0.80
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Mov Disord (2013) 0.79
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease. Drugs (2016) 0.78
Recent advances in the management of choreas. Ther Adv Neurol Disord (2013) 0.77
The P42 peptide and Peptide-based therapies for Huntington's disease. Orphanet J Rare Dis (2016) 0.75
Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology (2006) 3.87
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol (2010) 3.47
A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet (1974) 2.17
Huntington's disease: a clinical review. Orphanet J Rare Dis (2010) 2.12
Stigma of epilepsy. Can J Neurol Sci (2008) 1.65
Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI). Qual Life Res (2009) 1.63
Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry (1999) 1.63
Huntington's disease: clinical correlates of disability and progression. Neurology (2003) 1.52
Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord (2005) 1.51
Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol (2007) 1.47
Earliest functional declines in Huntington disease. Psychiatry Res (2010) 1.45
'When I am together with them I feel more ill.' The stigma of multiple sclerosis experienced in social relationships. Chronic Illn (2006) 1.45
Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci (2001) 1.32
Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev (2009) 1.30
Falls and gait disturbances in Huntington's disease. Mov Disord (2008) 1.20
Awareness of involuntary movements in Huntington disease. Arch Neurol (1998) 1.16
The current clinical management of Huntington's disease. Mov Disord (2008) 1.16
Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol (2009) 1.15
Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature. J Child Neurol (2006) 1.12
Predictors of nursing home placement in Huntington disease. Neurology (2003) 1.11
Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des (2006) 1.09
Symptomatic treatment of Huntington disease. Neurotherapeutics (2008) 1.08
Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet (2010) 1.05
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry (1997) 1.05
Bradykinesia in early Huntington's disease. Neurology (2000) 1.05
Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol (2001) 1.05
Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol (1999) 1.03
Late onset Huntington Disease: clinical and genetic characteristics of 34 cases. J Neurol Sci (2008) 1.01
Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology (1988) 0.94
A randomized trial of amantadine in Huntington disease. Arch Neurol (2003) 0.94
Huntington disease in a 9-year-old boy: clinical course and neuropathologic examination. J Child Neurol (2006) 0.92
Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics (2005) 0.92
Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin (1984) 0.92
Evidence for a disorder of locomotor timing in Huntington's disease. Mov Disord (2005) 0.91
Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol (2006) 0.91
Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res (2004) 0.90
Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol (2002) 0.90
Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology. Brain Res (2007) 0.90
Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review. Neurorehabil Neural Repair (2003) 0.89
Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry (2008) 0.88
Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord (2009) 0.87
[Public attitudes towards alcohol dependence]. Psychiatr Prax (2010) 0.85
In motion, out of place: the public space(s) of Tourette Syndrome. Soc Sci Med (2004) 0.84
IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology (2004) 0.84
An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease. PLoS Curr (2011) 0.81
An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease. PLoS Curr (2011) 0.81
Clonazepam in the treatment of choreiform activity. Med J Aust (1976) 0.80
Tiapride in 12 Huntington's disease patients. J Neurol Neurosurg Psychiatry (1985) 0.78
Management of Huntington's disease: role of tetrabenazine. Ther Clin Risk Manag (2011) 0.78
[Olanzapine improves chorea in patients with Huntington's disease]. Rev Neurol (2002) 0.78
Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science (2010) 18.45
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
T1DBase: integration and presentation of complex data for type 1 diabetes research. Nucleic Acids Res (2006) 3.25
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol (2007) 2.24
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
The value of positron emission tomography in the clinical evaluation of dementia. J Am Geriatr Soc (2003) 2.05
Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry (2002) 1.96
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Mov Disord (2011) 1.68
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain (2007) 1.66
Challenges assessing clinical endpoints in early Huntington disease. Mov Disord (2010) 1.66
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res (2007) 1.63
Detailed transcriptome atlas of the pancreatic beta cell. BMC Med Genomics (2009) 1.55
Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord (2012) 1.54
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Clinical feature profile of spinocerebellar ataxia type 1-8 predicts genetically defined subtypes. Mov Disord (2005) 1.49
T1DBase, a community web-based resource for type 1 diabetes research. Nucleic Acids Res (2005) 1.44
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain (2009) 1.44
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
An approach to the patient with late-onset cerebellar ataxia. Nat Clin Pract Neurol (2006) 1.40
Novel mutations in the senataxin DNA/RNA helicase domain in ataxia with oculomotor apraxia 2. Neurology (2006) 1.37
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord (2010) 1.29
A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol (2008) 1.25
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet (2002) 1.19
Common data elements for clinical research in Friedreich's ataxia. Mov Disord (2012) 1.14
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci (2008) 1.12
Mutations in rare ataxia genes are uncommon causes of sporadic cerebellar ataxia. Mov Disord (2012) 1.10
Automatic activation of the semantic network in schizophrenia: evidence from event-related brain potentials. Biol Psychiatry (2003) 1.10
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord (2005) 1.05
Factor analytic support for social cognition as a separable cognitive domain in schizophrenia. Schizophr Res (2007) 1.04
Differential patterns of premorbid academic and social deterioration in patients with schizophrenia. Schizophr Res (2005) 1.03
Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. Eur J Hum Genet (2007) 1.03
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (2003) 1.02
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord (2005) 1.01
Depressive and memory symptoms as presenting features of spinocerebellar ataxia. J Neuropsychiatry Clin Neurosci (2006) 0.99
The past, present, and future of telemedicine for Parkinson's disease. Mov Disord (2014) 0.97
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain (2009) 0.96
Self Reports of Day-to-Day Function in a Small Cohort of People with Prodromal and Early HD. PLoS Curr (2011) 0.96
Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest (2013) 0.95
A gene expression phenotype in lymphocytes from Friedreich ataxia patients. Ann Neurol (2011) 0.94
Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord (2008) 0.93
Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet (2008) 0.91
Aberrant splicing of the senataxin gene in a patient with ataxia with oculomotor apraxia type 2. Cerebellum (2009) 0.90
Comprehensive phenotype of the p.Arg420his allelic form of spinocerebellar ataxia type 13. Cerebellum (2013) 0.89
Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants. J Child Neurol (2012) 0.89
Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One (2012) 0.88
Health related quality of life measures in Friedreich Ataxia. J Neurol Sci (2008) 0.87
NOTCH4 gene haplotype is associated with schizophrenia in African Americans. Biol Psychiatry (2004) 0.87
Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol (2004) 0.87
The language system in schizophrenia: effects of capacity and linguistic structure. Schizophr Bull (2002) 0.87
[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. Mov Disord (2015) 0.86
SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs. Nat Commun (2013) 0.86
Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biol Psychiatry (2003) 0.86
Assessment of depression, anxiety and apathy in prodromal and early huntington disease. PLoS Curr (2011) 0.86
Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. Brain Res (2007) 0.86
Assessing behavioural manifestations prior to clinical diagnosis of huntington disease: "anger and irritability" and "obsessions and compulsions". PLoS Curr (2011) 0.84
Oculomotor and visual axis systems sparing in spinocerebellar ataxia type 13(R420H). Neurology (2012) 0.83
Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord (2003) 0.83
Analysis of the visual system in Friedreich ataxia. J Neurol (2013) 0.83
Semantic memory in schizophrenia: association with cell membrane essential fatty acids. Schizophr Res (2008) 0.83
Association study of DTNBP1 with schizophrenia in a US sample. Psychiatr Genet (2009) 0.82
Assessment of motor symptoms and functional impact in prodromal and early huntington disease. PLoS Curr (2011) 0.82
A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends. Neuroepidemiology (2014) 0.81
Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol (2007) 0.81
Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann Neurol (2002) 0.81
An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease. PLoS Curr (2011) 0.81
Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (2004) 0.81
An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease. PLoS Curr (2011) 0.81
Piloting the NPF data-driven quality improvement initiative. Parkinsonism Relat Disord (2010) 0.80
Assessment of Day-to-Day Functioning in Prodromal and Early Huntington Disease. PLoS Curr (2011) 0.80
A proposed bailout for A-T patients? Eur J Neurol (2009) 0.80
Clinical evaluation of eye movements in spinocerebellar ataxias: a prospective multicenter study. J Neuroophthalmol (2015) 0.80
CALCYON gene variation, schizophrenia, and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet (2004) 0.80
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res (2012) 0.79
Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem. Schizophr Res (2008) 0.79
Coenzyme Q10 and spinocerebellar ataxias. Mov Disord (2014) 0.79
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med (2011) 0.78
The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. J Clin Pharmacol (2007) 0.78
Assessment of cognitive symptoms in prodromal and early huntington disease. PLoS Curr (2011) 0.78
Population admixture modulates risk for alcohol dependence. Hum Genet (2009) 0.78
A family with combined mutations of the hemophilia A and X-linked adrenoleukodystrophy genes. Neurogenetics (2008) 0.77
Late-onset pure cerebellar ataxia: differentiating those with and without identifiable mutations. J Neurol Sci (2005) 0.76
Medical image. "Hot cross bun" sign. N Z Med J (2007) 0.75